Skip to main content
. 2022 Mar 17;4(5):e338–e350. doi: 10.1016/S2665-9913(22)00034-0

Figure 4.

Figure 4

Humoral response following a third SARS-CoV-2 vaccination

Seroconversion and anti-RBD IgG titres up to the third SARS-CoV-2 vaccination. The percentage (with error bars indicating 95% CIs) of participants with seroconversion (ie, anti-RBD IgG titre >4 AU/mL) 28 days after each vaccination for different immunosuppressant groups (A) and the control group (B) are shown. The dark coloured parts of the bars represent the proportion of participants who remained seropositive after their second vaccination. The anti-RBD IgG titres for different immunosuppressant groups (C) and the control group (D), from before first vaccination to after third vaccination, are shown. Vertical dashed lines represent first, second, and third vaccine doses. Dots represent serum samples before first vaccination, 28 days after first vaccination, at second vaccination (day 42; absent in MMF plus other immunosuppressant group and S1P modulator group), 10 days after second vaccination (day 52), 28 days after second vaccination (day 70), at third vaccination (day 190), 7 days after third vaccination (day 197; absent in MMF plus other immunosuppressant group), and 28 days after third vaccination (day 218). AU=arbitrary unit. MMF=mycophenolate mofetil. RBD=receptor binding domain. S1P=sphingosine 1-phosphate receptor. T1=28 days after first vaccination. T2=28 days after second vaccination. T3=28 days after third vaccination. TNF=tumour necrosis factor. *Details on other immunosuppressants are shown in the appendix (pp 5–6). †The control group is composed of healthy controls and patients with immune-mediated inflammatory disorders not on immunosuppressants.